JAMES WELSH to Mice
This is a "connection" page, showing publications JAMES WELSH has written about Mice.
Connection Strength
0.953
-
Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3. J Nanobiotechnology. 2024 Oct 01; 22(1):597.
Score: 0.055
-
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. J Exp Clin Cancer Res. 2024 Mar 06; 43(1):70.
Score: 0.052
-
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight. 2023 06 22; 8(12).
Score: 0.050
-
NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model. Cancer Immunol Immunother. 2023 Sep; 72(9):3003-3012.
Score: 0.050
-
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res. 2023 04 03; 11(4):486-500.
Score: 0.049
-
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol. 2022; 13:1022011.
Score: 0.048
-
Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol. 2022; 13:984318.
Score: 0.048
-
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology. 2022 Sep 19; 20(1):417.
Score: 0.047
-
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2).
Score: 0.041
-
Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 09 24; 11(1):4840.
Score: 0.041
-
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. 2020 06; 8(1).
Score: 0.040
-
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020 07; 8(7):883-894.
Score: 0.040
-
Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. Clin Cancer Res. 2019 12 15; 25(24):7576-7584.
Score: 0.039
-
IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):903-912.
Score: 0.037
-
Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects. Front Immunol. 2018; 9:2170.
Score: 0.036
-
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res. 2018 11 15; 24(22):5735-5743.
Score: 0.035
-
Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett. 2018 09 01; 431:54-63.
Score: 0.035
-
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
Score: 0.032
-
PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016 Jan; 108(1).
Score: 0.030
-
Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
Score: 0.027
-
Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014 Aug; 22(8):1494-1503.
Score: 0.027
-
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 2009 Dec 22; 4:69.
Score: 0.020
-
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024 Sep 02; 43(1):251.
Score: 0.014
-
A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. J Nanobiotechnology. 2021 Dec 11; 19(1):416.
Score: 0.011
-
Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects. Int J Radiat Oncol Biol Phys. 2021 11 01; 111(3):647-657.
Score: 0.011
-
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2).
Score: 0.010
-
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447.
Score: 0.009
-
Radiation therapy and immunotherapy: what is the optimal timing or sequencing? Immunotherapy. 2018 02 01; 10(4):299-316.
Score: 0.009
-
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013 Sep; 23(9):1446-61.
Score: 0.006
-
WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev. 2000 Mar 01; 14(5):585-95.
Score: 0.002
-
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A. 1998 Dec 08; 95(25):14717-22.
Score: 0.002